1234. Randomized Evaluation of Decolonization vs. Universal Clearance to Eliminate Methicillin-Resistant Staphylococcus aureus in ICUs (REDUCE MRSA Trial)
Session: Oral Abstract Session: Featured Abstract: Epidemiology and Infection Control
Friday, October 19, 2012: 4:15 PM
Room: Ballroom 20 ABCD

Background: Many states mandate screening of ICU admissions for carriage of MRSA. However, universal decolonization without screening might be a better strategy to reduce MRSA prevalence and prevent infection due to a broader set of pathogens.

Methods: We conducted a 3 arm cluster-randomized trial of MRSA prevention strategies. Study design included a 1-year baseline period (Jan-Dec 2009) and an 18-month intervention period (Apr 2010 - Sept 2011). All ICUs in a hospital were assigned to the same strategy. These were 1) screening and isolation: nasal MRSA screening followed by isolation if positive, 2) targeted decolonization: screening, followed, if positive, by isolation and decolonization with chlorhexidine baths and mupirocin for 5 days, and 3) universal decolonization: stop screening, add universal use of mupirocin for 5 days and daily chlorhexidine baths for the duration of ICU stay. Proportional hazards models with shared frailties were used to assess differences in infection reductions across the arms, accounting for clustering by hospital. The primary analysis was as-randomized and unadjusted. A secondary analysis adjusted for age, gender, race, payer, comorbidities, and prior MRSA history.

Results: We randomized 43 hospitals in 16 states. There were 74 adult ICUs with 48,390 admissions in the baseline period and 74,256 in the intervention period. There were significant differences between arms in the relative hazards for intervention vs. baseline for both clinical isolates of MRSA and bloodstream infections caused by all pathogens (Table). In each case, universal decolonization produced a significantly greater reduction than screening and isolation. Targeted decolonization was not significantly different from screening and isolation alone. Adjusted analyses yielded similar results (Table).

Conclusion: Universal decolonization with chlorhexidine and mupirocin in adult ICUs yielded a 37% reduction in risk of an MRSA clinical isolate and a 44% reduction in risk of bloodstream infections due to all pathogens. Decolonizing all ICU patients was more effective than screening for MRSA. It also eliminated the need for surveillance cultures and reduced the need for isolation precautions.

Susan S. Huang, MD, MPH, FIDSA1, Edward Septimus, MD, FIDSA, FSHEA2, Ken Kleinman, ScD3, Julia Moody, MS2, Jason Hickok, MBA2, Taliser Avery, MS4, Julie Lankiewicz, MPH5, Adrijana Gombosev, BS6, Leah Terpstra, BA6, Fallon Hartford, MS3, Mary Hayden, MD, FSHEA7, John A. Jernigan, MD, MS8,9, Robert Weinstein, MD10, Victoria J. Fraser, MD, FIDSA, FSHEA11, Katherine Haffenreffer, BS3, Eric Cui, BS6, Rebecca E. Kaganov, BA5, Karen Lolans, BS12, Jonathan Perlin, MD2, Richard Platt, MD, MS, FSHEA3 and the CDC Prevention Epicenters and the AHRQ DEcIDE Network and Healthcare-Associated Infections Program, (1)University of California Irvine School of Medicine, Orange, CA, (2)Clinical Services Group, HCA Inc, Nashville, TN, (3)Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, (4)Department of Population Medicine, Harvard Medical School, Boston, MA, (5)Harvard Pilgrim Health Care Institute, Boston, MA, (6)Division of Infectious Diseases and Health Policy Research Institute, University of California Irvine School of Medicine, Irvine, CA, (7)Rush University Medical Center, Chicago, IL, (8)Division of Healthcare Quality Promotion, Centers for Diseases Control and Prevention, Atlanta, GA, (9)Centers for Diseases Control and Prevention, Atlanta, GA, (10)John Stroger Hospital, Chicago, IL, (11)Department of Medicine, Washington University School of Medicine, St. Louis, MO, (12)Rush Univ. Med. Ctr., Chicago, IL

Disclosures:

S. S. Huang, None

E. Septimus, Cubist: Speaker's Bureau, Speaker honorarium
Sage: Speaker's Bureau, Speaker honorarium
3M: Scientific Advisor, Consulting fee

K. Kleinman, None

J. Moody, None

J. Hickok, None

T. Avery, None

J. Lankiewicz, None

A. Gombosev, None

L. Terpstra, None

F. Hartford, None

M. Hayden, Sage Inc: Product support only, 2% chlorhexidine cloths provided for a research project

J. A. Jernigan, None

R. Weinstein, Sage: Receiver of product support, Product support for research projects

V. J. Fraser, National Institutes of Health: Grant Investigator, Grant recipient
Centers for Disease Control and Prevention: Grant Investigator, Grant recipient
Agency for Healthcare Research and Quality: Grant Investigator, Grant recipient
Battelle: Consultant, Consulting fee
Express Scripts: Shareholder, Dividends
The Foundation for Barnes-Jewish Hospital: Grant Investigator, Grant recipient

K. Haffenreffer, None

E. Cui, None

R. E. Kaganov, None

K. Lolans, None

J. Perlin, None

R. Platt, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.